JP2020524178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524178A5 JP2020524178A5 JP2020515285A JP2020515285A JP2020524178A5 JP 2020524178 A5 JP2020524178 A5 JP 2020524178A5 JP 2020515285 A JP2020515285 A JP 2020515285A JP 2020515285 A JP2020515285 A JP 2020515285A JP 2020524178 A5 JP2020524178 A5 JP 2020524178A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- compound according
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 12
- 108020002908 Epoxide hydrolase Proteins 0.000 claims description 10
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 10
- 102100038495 Bile acid receptor Human genes 0.000 claims description 8
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- 235000009200 high fat diet Nutrition 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims description 2
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000283074 Equus asinus Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims description 2
- 241000700159 Rattus Species 0.000 claims description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 0 C*c(cc1)c(*)c(*)c1C(*N*)=O Chemical compound C*c(cc1)c(*)c(*)c1C(*N*)=O 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/062692 WO2018215070A1 (en) | 2017-05-24 | 2017-05-24 | Dual modulators of farnesoid x receptor and soluble epoxide hydrolase |
| EPPCT/EP2017/062692 | 2017-05-24 | ||
| PCT/EP2018/063699 WO2018215610A1 (en) | 2017-05-24 | 2018-05-24 | Dual modulators of farnesoid x receptor and soluble epoxide hydrolase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524178A JP2020524178A (ja) | 2020-08-13 |
| JP2020524178A5 true JP2020524178A5 (enExample) | 2021-07-26 |
Family
ID=58873803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515285A Pending JP2020524178A (ja) | 2017-05-24 | 2018-05-24 | ファルネソイドｘ受容体および可溶性エポキシドヒドロラーゼの二重調節剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200172473A1 (enExample) |
| EP (1) | EP3630085A1 (enExample) |
| JP (1) | JP2020524178A (enExample) |
| KR (1) | KR20200010387A (enExample) |
| CN (1) | CN110891560A (enExample) |
| AU (1) | AU2018274652A1 (enExample) |
| BR (1) | BR112019023820A2 (enExample) |
| CA (1) | CA3062388A1 (enExample) |
| IL (1) | IL270736A (enExample) |
| RU (1) | RU2019143106A (enExample) |
| WO (2) | WO2018215070A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| US20220273593A1 (en) * | 2019-09-19 | 2022-09-01 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Compounds and compositions for treating kidney disease |
| EP4090327B1 (en) | 2020-01-15 | 2025-03-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| CN112062665A (zh) * | 2020-09-24 | 2020-12-11 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 2,5-双(2,6-二氟亚苄基)-环戊酮及其制备方法和应用 |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3830054A1 (de) * | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| ES2266227T3 (es) * | 2000-08-21 | 2007-03-01 | Pacific Corporation | Nuevos compuestos de (tio)urea y composiciones farmaceuticas que los contienen. |
| EP1303483B1 (en) * | 2000-08-21 | 2008-04-23 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| US20050009812A1 (en) * | 2001-10-05 | 2005-01-13 | Takuya Seko | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
| GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| CA2517888C (en) * | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| JP4737084B2 (ja) * | 2004-03-12 | 2011-07-27 | 堺化学工業株式会社 | アミド化合物、医薬組成物及びｒｘｒ機能調節剤 |
| WO2007050124A1 (en) * | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| WO2008120759A1 (ja) * | 2007-03-30 | 2008-10-09 | Japan Tobacco Inc. | ウレア化合物およびその用途 |
| WO2008123469A1 (ja) * | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | ６員環アミド化合物およびその用途 |
| WO2008126731A1 (ja) * | 2007-04-05 | 2008-10-23 | Daiichi Sankyo Company, Limited | アリール誘導体 |
| WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
| CA2881070A1 (en) * | 2012-10-26 | 2014-05-01 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| CN105439914B (zh) * | 2014-09-17 | 2017-07-11 | 复旦大学 | 4‑氨酰基苯氧乙酰胺类化合物及其药物用途 |
| ES2907622T3 (es) * | 2014-10-06 | 2022-04-25 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de BTK y usos de estos |
| EP3230276B1 (en) * | 2014-12-10 | 2020-09-02 | Celgene International II Sarl | Glp-1 receptor modulators |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| WO2016144704A2 (en) * | 2015-03-11 | 2016-09-15 | Pharmakea, Inc. | Heterocyclic autotaxin inhibitor compounds |
| US10927069B2 (en) * | 2015-07-02 | 2021-02-23 | The Medical College Of Wisconsin, Inc. | Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors |
-
2017
- 2017-05-24 WO PCT/EP2017/062692 patent/WO2018215070A1/en not_active Ceased
-
2018
- 2018-05-24 WO PCT/EP2018/063699 patent/WO2018215610A1/en not_active Ceased
- 2018-05-24 CA CA3062388A patent/CA3062388A1/en not_active Abandoned
- 2018-05-24 RU RU2019143106A patent/RU2019143106A/ru not_active Application Discontinuation
- 2018-05-24 JP JP2020515285A patent/JP2020524178A/ja active Pending
- 2018-05-24 CN CN201880033893.6A patent/CN110891560A/zh active Pending
- 2018-05-24 BR BR112019023820A patent/BR112019023820A2/pt not_active Application Discontinuation
- 2018-05-24 US US16/614,785 patent/US20200172473A1/en not_active Abandoned
- 2018-05-24 KR KR1020197037508A patent/KR20200010387A/ko not_active Withdrawn
- 2018-05-24 EP EP18724926.3A patent/EP3630085A1/en not_active Withdrawn
- 2018-05-24 AU AU2018274652A patent/AU2018274652A1/en not_active Abandoned
-
2019
- 2019-11-18 IL IL270736A patent/IL270736A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524178A5 (enExample) | ||
| CN1501796A (zh) | 用二肽基肽酶iv抑制剂治疗2型糖尿病 | |
| RU2019143106A (ru) | Двойные модуляторы фарнезоидного x-рецептора и растворимой эпоксидгидролазы | |
| JP2004530669A5 (enExample) | ||
| JP2015535247A5 (enExample) | ||
| JP2004510705A5 (enExample) | ||
| CA2415577A1 (en) | Use of cox-2 inhibitors for preventing immunodeficiency | |
| JP2020515523A5 (enExample) | ||
| CN112384214A (zh) | 作为可溶性鸟苷酸环化酶激活剂的烷氧基吡唑 | |
| JP2005527575A5 (enExample) | ||
| RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
| JP4511183B2 (ja) | 神経変性疾患および心臓血管疾患の治療 | |
| JP2020533402A5 (enExample) | ||
| RU2275906C2 (ru) | Средство для лечения болезни паркинсона, включающее в качестве активного ингредиента соединение, улучшающее астроцитную функцию | |
| JP2019516726A5 (enExample) | ||
| JP5786714B2 (ja) | 神経障害性疼痛の治療剤又は予防剤 | |
| JP2006511604A5 (enExample) | ||
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| US11807604B1 (en) | Pharmaceutical compounds, pharmaceutical compositions, and methods of treating asthma and other disorders | |
| WO2002013864A1 (en) | Medicinal compositions for preventing and treating cancer | |
| CA2686787A1 (en) | Raf inhibitors for the treatment of thyroid cancer | |
| JP2018504391A5 (enExample) | ||
| RU2004109817A (ru) | Производные аминопиррола в качестве противовоспалительных средств | |
| JP2015533128A5 (enExample) |